2-(4-ethoxybenzyl)phenol | 360775-71-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-ethoxybenzyl)phenol
• 英文别名: 2-(4-ethyoxybenzyl)phenol；2-[(4-ethoxyphenyl)methyl]phenol
• CAS: 360775-71-9
• 化学式: C₁₅H₁₆O₂
• 分子量: 228.291
• InChiKey: BMPXABNSIVCIID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-ethoxybenzyl)phenol 生成 2-(4-ethoxybenzyl)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside
  参考文献：
  名称：

  Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same

  摘要：

  本发明涉及由通式表示的葡萄糖吡喃基氧基苯基苄基苯基衍生物：其中P代表形成前药的基团；R代表下位烷基基团、下位烷氧基基团、下位烷基硫基团、下位烷氧基取代的（下位烷基）基团、下位烷氧基取代的（下位烷氧基）基团或下位烷氧基取代的（下位烷基硫）基团，这些衍生物具有改善的口服吸收能力，在人体SGLT2中可以发挥出色的抑制活性，对于预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症等，以及包含这些衍生物的药物组合物，具有应用价值。

  公开号：

  US20040018998A1
• 作为产物：
  描述：

  2-苄氧基溴苯 在 盐酸 、 正丁基锂 、 氢气 、 palladium(II) hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 、 乙酸乙酯 为溶剂， 反应 17.33h， 生成 2-(4-ethoxybenzyl)phenol
  参考文献：
  名称：

  5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  5a-Carba-beta-D-glucopyranose derivatives were synthesized and identified as novel SGLT2-selective inhibitors. These inhibitors exhibited potent SGLT2 inhibition with high selectivity over SGLT1. Among the tested compounds, 6f indicated the most potent hSGLT2 inhibition and the highest selectivity over hSGLT1. Moreover, the pharmacokinetics data also showed that 6h, which had the same aglycon structure as sergliflozin-active (3-active), had a threefold longer half-life time (T(1/2)) than sergliflozin (3) with a high distribution volume in db/db mice. Subsequently, 6h lowered blood glucose levels as much as 3 and showed longer hypoglycemic action than 3 in db/db mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.005

文献信息

• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：Fujikura Hideki

  公开号：US20050080022A1

  公开（公告）日：2005-04-14

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃基氧基苄基苯衍生物：其中R1表示氢原子或羟基（较低烷基）基团；R2表示较低烷基基团、较低烷氧基团、较低烷基硫基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐。该化合物在人类SGLT2中具有优异的抑制活性，可用作预防或治疗糖尿病、肥胖等的药物，以及其中间体。
• Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides
  申请人：Sato Masakazu

  公开号：US20050256317A1

  公开（公告）日：2005-11-17

  The present invention provides a method for preparing an aryl 5-thio-β-D-aldohexopyranoside derivative of Formula (III), which comprises reacting a 5-thio-D-aldohexopyranose derivative of Formula (I) with Ar—OH of Formula (II) in the presence of a phosphine represented by PR 11 R 12 R 13 and an azo reagent represented by R 21 —N═N—R 22 in accordance with the following scheme.

  本发明提供了一种制备式（III）的芳基5-硫代β-D-醛基己糖苷衍生物的方法，其中包括在磷化物PR11R12R13和偶氮试剂R21-N═N-R22的存在下，将式（I）的5-硫代-D-醛基己糖苷衍生物与式（II）的Ar—OH反应，反应方案如下：
• Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
  申请人：Sato Masakazu

  公开号：US20050209309A1

  公开（公告）日：2005-09-22

  There is provided a 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

  提供了一种具有SGLT2活性抑制作用的5-硫代-β-D-葡萄糖吡喃糖苷化合物，或其药学上可接受的盐或水合物。还提供了一种制药制剂，特别是预防或治疗糖尿病、糖尿病相关疾病或糖尿病并发症的药物，其包含该化合物作为活性成分。
• Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：——

  公开号：US20040053855A1

  公开（公告）日：2004-03-18

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式1所表示的葡萄糖吡喃基氧基苯基苯基衍生物，其中R1代表氢原子或羟基（较低烷基）基团；R2代表较低烷基基团、较低烷氧基基团、较低烷基硫基基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐，具有出色的人类SGLT2抑制活性，并可用作糖尿病、肥胖等的预防或治疗药物及其中间体。
• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。